Pertussis acellular vaccine low-dose (GlaxoSmithKline)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePertussis acellular vaccine low-dose (GlaxoSmithKline)
Drug Alias NameReduced antigen content tri-component acellular pertussis vaccine - GlaxoSmithKlineGSK-251154
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsWhooping Cough
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsWhooping Cough

Other Information

ATC CodeN/A
Related LinksN/A